[company_age]7.0[/company_age][employees]11-50 employees[/employees][funding]debt_financing[/funding][description]Cardurion Pharmaceuticals is a next-generation cardiovascular company dedicated to developing groundbreaking treatments for patients with cardiovascular disease. The company leverages its world-class expertise in cardiovascular signaling pathways to discover and develop novel drug candidates. Cardurion's unique approach includes innovative trial designs, precision medicine strategies, and strategic acquisitions. The company has two groundbreaking clinical programs in development: a PDE9 inhibitor program for heart failure and a CaMKII inhibitor program for multiple cardiovascular indications. Cardurion is committed to changing the course of cardiovascular disease for patients.[/description][ps]PDE9 and CaMKII inhibitors for cardiovascular diseases.[/ps]